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ABSTRACT
ObjeCtive
To compare the annual prevalence of the autism 
symptom phenotype and of registered diagnoses for 
autism spectrum disorder during a 10 year period in 
children.
Design
Population based study.
setting
Child and Adolescent Twin Study and national patient 
register, Sweden.
PartiCiPants
19 993 twins (190 with autism spectrum disorder) and 
all children (n=1 078 975; 4620 with autism spectrum 
disorder) born in Sweden over a 10 year period from 
1993 to 2002.
Main OutCOMe Measures
Annual prevalence of the autism symptom phenotype 
(that is, symptoms on which the diagnostic criteria are 
based) assessed by a validated parental telephone 
interview (the Autism-Tics, ADHD and other 
Comorbidities inventory), and annual prevalence of 
reported diagnoses of autism spectrum disorder in the 
national patient register.
results
The annual prevalence of the autism symptom 
phenotype was stable during the 10 year period 
(P=0.87 for linear time trend). In contrast, there was a 
monotonic significant increase in prevalence of 
registered diagnoses of autism spectrum disorder in 
the national patient register (P<0.001 for linear trend).
COnClusiOns
The prevalence of the autism symptom phenotype has 
remained stable in children in Sweden while the 
official prevalence for registered, clinically diagnosed, 
autism spectrum disorder has increased substantially. 
This suggests that administrative changes, affecting 
the registered prevalence, rather than secular factors 
affecting the pathogenesis, are important for the 
increase in reported prevalence of autism spectrum 
disorder.
Introduction
Autism spectrum disorder comprises a group of disor-
ders characterised by deficits in social communication 
interaction and behavioural flexibility.1  From the 1970s 
and onwards the reported prevalence of autism spec-
trum disorder has increased substantially. The condi-
tion was considered rare, affecting fewer than 0.05% of 
the population,2-5  but it is now generally agreed that the 
lifetime prevalence is at least 1% in both young people 
and adults.6 7  Several of the most recent studies report 
an even higher prevalence; researchers in South Korea 
estimated the prevalence of autism spectrum disorder 
or pervasive developmental disorder in 7-12 year olds to 
be 2.6% using a screening procedure followed up by a 
clinical assessment.8  In the United States, the Centers 
for Disease Control and Prevention reported a mono-
tonic increase of autism spectrum disorder in school 
aged children, peaking at 2% in 2012.9  This figure was 
obtained by a telephone survey where parents were 
asked if they had ever been told by a healthcare pro-
vider that their child had an autism spectrum disorder, 
and if their child currently had an autism spectrum dis-
order. Finally, a record linkage study in Sweden, using 
a multisource approach of all trajectories to a diagnosis 
of an autism spectrum disorder in Stockholm county, 
reported that 2.5% of all teenagers had received a clini-
cal diagnosis of autism spectrum disorder.10
Despite the increase in reported prevalence of autism 
spectrum disorder, there is no direct evidence that this 
corresponds to an increase in the prevalence of the 
autism phenotype—that is, the symptoms on which the 
diagnostic criteria are based. This is due to several fac-
tors. Firstly, the increase in the prevalence was reported 
during a period of repeated modifications and often 
broadening of diagnostic criteria,4  which clearly affects 
the reported prevalence.11 12  Secondly, increasing 
awareness of autism spectrum disorder is associated 
with diagnostic substitution across categories. It has 
been estimated that one third of the prevalence increase 
of autism spectrum disorder between 1996 and 2004 
WhAT IS AlReAdy knoWn on ThIS TopIC
Numerous studies have suggested that the prevalence of autism spectrum disorder 
has increased substantially, and some recent studies have reported a population 
prevalence that exceeds 2%
Much of the prevalence increase can be explained by a broadening of the 
diagnostic criteria for autism spectrum disorder, although studies are biased by 
increased public and professional awareness, diagnostic substitution, and age at 
referral
Thus it is unclear if the increase in prevalence reflects an actual increase in the 
autism symptom phenotype
WhAT ThIS STudy AddS
Our findings do not support a secular increase in the rate of the autism symptom 
phenotype
Administrative factors that affect the registered prevalence may therefore account 
for much of the increase in the reported prevalence of autism spectrum disorder
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could be attributed to diagnostic substitution,13  and the 
increase in autism spectrum disorder has been sug-
gested to parallel a decrease in learning disabilities and 
mental retardation.14  15  Thirdly, prevalence is also sen-
sitive to referral patterns and availability of services.16 
Finally, methodological differences in case ascertain-
ment and assessment alter prevalence—for instance, 
the availability of, and discrepancies within, official 
records give rise to large variations between measured 
and actual prevalence in similar geographical regions.17 
Consequently, the reported increase in prevalence of 
autism spectrum disorder remains difficult to interpret. 
Determining if the prevalence is actually increasing has 
major public health implications, such as in the alloca-
tion of adequate health resources and research efforts 
to find the causes of autism spectrum disorder.
We monitored the annual prevalence of the autism 
symptom phenotype in children born between 1993 
and 2002 in a Swedish total population twin sample 
using the same validated instrument, and contrasted 
these data with the annual prevalence of clinical diag-
noses of autism spectrum disorder according to data 
held in the national patient register in Sweden. By 
comparing a standardised measure in an assessed and 
defined population sample with clinical service diag-
nostic records by services for the same area, we hoped 
to clarify whether differences in diagnostic rates 
 represent the population prevalence measured inde-
pendently of  services.
Methods
Participants
We used two sources to estimate the prevalence of 
autism spectrum disorder: the Child and Adolescent 
Twin Study in Sweden and the Swedish national patient 
register. These studies have ethical approval from the 
Karolinska Institutet ethical review board (Dnr 02-289 
and 2010/507-31/1).
Child and Adolescent Twin Study in Sweden
Beginning in 2004 the parents of all Swedish twins born 
since July 1992 are contacted in connection with the 
twins’ ninth or 12th birthday; twins born from 1 July 
1992 to 31 June 1995 were included at age 12. After that 
(those born from 1 July 1995 onwards) only 9 year olds 
are included and asked to participate in the ongoing 
Child and Adolescent Twin Study in Sweden. The study 
has a response rate of 75% and is described in detail 
elsewhere.18 In the present study we included 19 993 
twins born in the 10 year period from 1 January 1993 to 
31 December 2002 whose parents had responded to the 
Autism-Tics, ADHD and other Comorbidities inventory.
The Child and Adolescent Twin Study in Sweden 
 contains a psychiatric telephone interview, the Autism-
Tics, ADHD and other Comorbidities inventory,19  which 
is a fully structured interview and was designed for use 
by laymen over the telephone. It consists of 96 ques-
tions, of which 17 correspond to an autism spectrum 
disorder domain, with an α of 0.86,18  and are scored 1 
for “yes,” 0.5 for “yes, to some extent,” and 0 for “no.” 
Out of the 17 items, six correspond to a language and 
communication module, six to a social interaction mod-
ule, and five to a restricted and repetitive behaviour 
module. We used a clinically validated cut-off for 
autism spectrum disorder of ≥8.5 to define the autism 
symptom phenotype. This cut-off has a Cohen’s κ value 
of 1.0,20  sensitivity of 0.71, and specificity of 0.95 for 
autism spectrum disorder when cases are compared 
cross sectionally with controls, and 0.61 and 0.91, 
respectively, when compared with a community 
 sample.21  In addition, a clinical longitudinal follow-up 
assessment yielded a sensitivity of 0.30 and specificity 
of 0.99 for autism spectrum disorder.22  The domain has 
also been independently validated by other research-
ers, and excellent psychometric properties have been 
reported.23
The 17 questions constituting the basis for the autism 
spectrum disorder domain have been the same since 
the start of the study. They were modelled around the 
pervasive developmental disorder (autistic disorder, 
299.00) phenotype of the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition.24  To 
increase reliability and validity, the Autism-Tics, ADHD 
and other Comorbidities inventory was constructed so 
as not to disclose which questions pertain to which dis-
order, to be administered by laymen over the phone and 
thus be independent of clinical preference or knowl-
edge, to avoid adherence to mutually exclusive criteria, 
and to evaluate lifetime presence of symptoms and 
behaviours. Taken together, this structure removes 
biases resulting from increased public and professional 
awareness, diagnostic substitution, changes in diag-
nostic concepts, and age at referral, making the Autism-
Tics, ADHD and other Comorbidities inventory suitable 
for the identification of real changes in the prevalence 
of proxy diagnoses for autism spectrum disorder over 
time. The inventory is freely available as an appendix.21
National patient register
At birth, or on receiving Swedish citizenship, all indi-
viduals living in Sweden are assigned a personal 
 identification number, which enables linkage across 
health and service registers. The Swedish national 
patient register25  provided data on all inpatient psychi-
atric care from 1987-2009 and includes best estimate 
specialist diagnoses assigned according to ICD-9 and 
ICD-10 codes (international classification of diseases, 
ninth and 10th revisions, respectively).26  27  Since 2001 
the national patient register also includes information 
from outpatient consultations with specialists. To esti-
mate the population prevalence of reported diagnoses 
of autism spectrum disorder we used data from the 
national patient register on 1 078 975 children born from 
1 January 1993 to 31 December 2002. Diagnostic codes 
retrieved were: ICD-9 299A and ICD-10 f84.0, f84.1, f84.5, 
and f84.9. The validity of the national patient register is 
continuously monitored; in a validation study that 
included the national patient register,28  the agreement 
for a registered diagnosis of autism spectrum disorder 
with diagnosis made after careful scrutiny of the medi-
cal records on which the registered diagnosis was made 
was reported to be 96.0% (confidence interval 92.0% 
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to 98.4%).28 In the current study we evaluated the cor-
rectness of the diagnosis of cases listed in the register 
but did not estimate false negative results. Therefore 
although the positive predictive value is high, the prev-
alence can increase without affecting the positive 
 predictive value.
Comparison between the register and the twin study
To allow comparability with data from the Child and 
Adolescent Twin Study in Sweden we only included 
children who had been born between 1 January 1993 
and 31 December 2002, had been given a diagnosis of 
autism spectrum disorder, and appeared in the 
national patient register before their 10th birthday. 
Given that the register currently includes diagnostic 
data up to 31 December 2009, children born during 
2000-02 had only 7-9 years of follow-up, whereas those 
born before 2000 had a follow-up of 10 years. We then 
merged the data from the twin study with that from the 
national patient register. (See supplementary table 1 on 
bmj.com for a description of the annual agreement 
between Autism-Tics, ADHD and other Comorbidities 
inventory and the national patient register in people 
screen positive for an autism spectrum disorder.) The 
sensitivity and specificity for a diagnosis based on the 
Autism-Tics, ADHD and other Comorbidities inventory 
in the national patient register was 0.51 and 0.99, 
respectively. Finally, we compared the annual preva-
lence of diagnoses in the national patient register in all 
twins born in Sweden between 1993 and 2002, includ-
ing non-responders in the Child and Adolescent Twin 
Study in Sweden (n=26 953, see supplementary table 2 
on bmj.com) with the overall population in the national 
patient register data.
statistical analysis
We grouped the prevalence of autism spectrum disorder 
on an annual basis separately for the autism symptom 
phenotype in the Child and Adolescent Twin Study in 
Sweden (cut-off ≥8.5) and the national patient register 
(clinical diagnosis) samples; we used Wald type 95% 
confidence intervals. To carry out the Cochrane-Armitage 
test for trend, we used the PROC FREQ procedure in SAS 
to model time trends in prevalence across birth years and 
for the autism symptom phenotype and clinical diagno-
sis separately. The PROC REG procedure was used to con-
duct a linear regression with the mean annual prevalence 
of autism spectrum disorder (symptom phenotype and 
clinical diagnosis separately) as the dependent variable, 
and year of birth as the independent variable.
Sensitivity analyses were also conducted for a 
broader cut-off of screening symptom score (≥4.5, sensi-
tivity 0.91, specificity 0.8021), applying the same analy-
ses as described previously. In addition we applied the 
analysis of variance model using PROC ANOVA in SAS 
to test for differences between birth years in the contin-
uous autism score derived from the 17 items constitut-
ing the autism spectrum disorder domain. TUKEY’s test 
was used for paired comparisons.
We aimed to detect if there was a trend towards 
non-responders being more likely to be given a diagno-
sis throughout the years. To do this we conducted a 
logistic regression using PROC LOGISTIC in SAS with 
the annual prevalence of autism spectrum disorder 
from the national patient register as the dependent 
variable and year of birth, response in the Child and 
Adolescent Twin Study in Sweden, and their interac-
tion as predictors (as 1995 included no national patient 
register diagnoses in the non-responders we combined 
this category with that of 1994). The interaction effect 
captures whether the ratio of national patient register 
diagnoses in responders versus non-responders 
changes significantly by year of birth; the interaction 
was non-significant (Wald χ2 test 7.71, degrees of free-
dom 8, P=0.46). (See supplementary table 4 on bmj.
com for descriptive statistics.)
Patient involvement
There was no patient involvement in this study.
Results
Tables 1  and 2  present descriptive statistics and the 
prevalence for each birth year from the Child and Ado-
lescent Twin Study in Sweden and the national patient 
register as well as the sensitivity analyses. In the twin 
study the population prevalence of the autism symptom 
phenotype was 0.95% and the estimates for the 10 time 
points ranged from 0.52-1.59% (figure), with overlap-
ping confidence intervals at all time points (except 1993 
v 1994). The effect of time was not significant (P=0.85 for 
test of time trend) and the regression analysis showed 
no effect of birth year (R2=0.003, F0.023, P=0.882). The 
categorical sensitivity analyses (cut-off ≥4.5) revealed 
no time trend in the trend analyses (P=0.55) nor in the 
regression analysis (R2=0.019, F0.154, P=0.705). However, 
the continuous analyses on the autism score differed 
significantly (P=0.002) although with overlapping con-
fidence intervals at all time points. In supplementary 
table 3 the means of the three modules (language or 
communication, social interaction, and restricted and 
table 1 | Descriptive data on children born 1 january 1993 to 31 December 2002 in Child and adolescent twin study in sweden, and in the national 
patient register
Cut-off
asD/non-asD per birth year
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
≥8.5 12/2286 34/2100 17/2053 17/1926 23/2025 23/1835 14/1979 14/1826 13/1863 23/1910
≥4.5 68/2230 95/2039 66/2004 49/1894 68/1980 59/1799 71/1922 54/1786 61/1815 81/1852
Registered 
diagnosis
303/129 710 375/1 23 386 361/114 121 409/105 626 454/100 673 472/99 100 592/97 786 600/99 825 532/100 076 522/104 052
ASD=autism spectrum disorder.
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repetitive behaviour) constituting the autism score are 
presented on an annual basis.
In the national patient register the population preva-
lence was 0.42% (n=4620) and the estimates ranged from 
0.23-0.60%. There was an almost linear increase over the 
examined years (except for children born during 2000-02, 
where the follow-up was <10 years) and the test for time 
trend was significant (P<0.001). The effect of birth year 
was further supported by the results of the linear regres-
sion analysis (R2=0.778, F28.00, P=0.001).
Estimates of population prevalence were similar in 
twins in the national patient register, irrespective of par-
ticipation in the Child and Adolescent Twin Study in 
Sweden; 0.54%, albeit with some variation in point esti-
mates. At each time point the confidence intervals over-
lapped between twins in the national patient register and 
those in the general population. The test for the time 
trend was significant (P<0.001) and the regression anal-
ysis showed an effect of birth year (R2=0.401 F5.35, P=0.049 
(figure, also see supplementary table 2 on bmj.com).
discussion
Using unique, large Swedish population based 
resources, we found that the annual prevalence of the 
autism symptom phenotype was stable over a 10 year 
period when investigating 9 and 12 year old children, 
while simultaneously the annual prevalence of clini-
cally diagnosed autism spectrum disorder in a service 
based register steadily increased. In summary, our data 
do not support a secular increase in the rate of the 
autism symptom phenotype, suggesting that adminis-
trative factors that affect the registered prevalence may 
account for much of the rise in the reported prevalence 
of autism spectrum disorder.
strengths and limitations of this study
The main strengths of this study include the large sam-
ple sizes, the high response rate in a nationwide study, 
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and the use of a validated instrument for assessment, 
which removes biases of increased public and profes-
sional awareness, diagnostic substitution, changes in 
diagnostic concepts, and age at referral.
Our findings must be seen in the light of some limita-
tions. The Autism-Tics, ADHD and other Comorbidities 
inventory does not have perfect sensitivity or specificity, 
meaning that some degree of “diagnostic misclassifica-
tion” should be expected. However, the fact that the 
autism symptom phenotype appeared to be constant 
over time argues strongly against this being a major lim-
iting factor. If autism spectrum disorder had really 
increased in the population, the prevalence of the 
symptomatic phenotype would have been expected to 
increase in a similar way. Also, clinical examinations, 
which in an ideal study might have been preferred, are 
not feasible in a nationwide study sample and might be 
prone to the aforementioned biases. Twinning has been 
suggested to be associated with an increased risk for 
autism spectrum disorder.29 30  Large epidemiological 
studies, including the results from this study, have 
found no or only a slight increase in the risk of autism 
spectrum disorder among twins.31-33 It is therefore 
unlikely that twinning explains the findings from this 
study. Finally, the comparison between the Child and 
Adolescent Twin Study in Sweden and the national 
patient register should take into account differences in 
age and follow-up time. Parents of twins born during 
1993-95 were interviewed when the twins were 12 years 
old, and those born during 2000-02 only had 7-9 years 
of follow-up in the national patient register. As a conse-
quence there was a seeming decrease in the annual 
prevalence of autism spectrum disorder for those born 
in 2000-02. However, when only including those who 
had been registered with a diagnosis in the national 
patient register before the age of 7 years, and thus hav-
ing had exactly the same length of follow-up, a mono-
tonic increase from 0.07% (1993) to 0.43% (2002, 
P<0.001) was observed.
Comparison with other studies
The prevalence of 0.95% (95% confidence interval 
0.82% to 1.08%) for the autism symptom phenotype 
reported here should not be taken to be directly compa-
rable to that of other epidemiological studies, given 
methodological differences in case ascertainment and 
assessment. However, there is accumulating evidence 
that the prevalence may have been historically under-
estimated in children. The prevalence of the autism 
symptom phenotype—that is, a triad of social, commu-
nication or language, and behavioural problems was 
already reported to be 0.7% in the early 1980s3  when a 
population based sample of children born in 1971 were 
assessed at early school age. Many of the children iden-
tified with this triad of difficulties were later shown to 
meet the—then newly formulated—criteria for Asperger 
syndrome,34  suggesting that the autism symptom phe-
notype may actually have been largely stable for the 
past three to four decades. Children with what currently 
would be labelled as autism spectrum disorder were in 
the past given other diagnoses or descriptions, includ-
ing developmental language disorder35  and schizophre-
nia or psychotic behaviour36  37  as well as borderline 
personality disorder.38 These diagnostic substitutions 
probably reflect the zeitgeist in professional knowledge 
and the overlap in symptoms between disorders.
Even though it is not possible to completely rule out 
the effect of secular environmental changes related to 
the pathogenesis of autism spectrum disorder, the 
results indicate that their effect over the past decade 
may be marginal. This conclusion is supported by the 
results from two cross sectional studies employing a 
screening followed by clinical follow-up of children 
born in the same geographical area between 1992 and 
199539  and 1996 and 1998,40  where no difference in 
prevalence over time was found. A recent study, using 
data from official registries from 1982-2006, found 
steady rates of relative recurrence risks in family mem-
bers, irrespective of population prevalence.41 This 
argues against secular environmental factors of large 
impact.
Conclusions and policy implications
We believe that our findings indicate that the preva-
lence of autism spectrum disorder is not increasing in 
childhood. The research and clinical resources cur-
rently devoted to dealing with these problems relate to 
the possibly mistaken notion that there is an actual 
increase. This allocation of specific resources to study 
“the epidemic of autism” should not be allowed to spi-
ral out of proportion. Other developmental disorders, 
such as intellectual developmental disorder, language 
disorder, and attention-deficit/hyperactivity disorder 
may recently have become overshadowed and seem to 
be missed diagnoses in many instances, where now 
only autism spectrum disorder is diagnosed (even per-
haps when the autism symptomatology is relatively 
mild). There is growing evidence that these other devel-
opmental disorders are at least as good as or perhaps 
even better indicators of outcome (and hence, some-
times, need for intervention) as autism spectrum disor-
der in itself.42  Research and clinical practice need to 
refocus on the child’s overall clinical situation and to 
acknowledge that autism is but one of the many Early 
Symptomatic Syndromes Eliciting Neurodevelopmental 
Clinical Examinations (ESSENCE).43  Children who are 
clinically impaired at an early age and who meet the 
criteria for autism spectrum disorder almost always 
have other developmental disorders and problems that 
need to be tackled.44 Clinics specialising in autism spec-
trum disorder are unlikely to be able to cater to all the 
needs of affected children and their families.
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